回盛生物
(300871)
| 流通市值：43.14亿 | | | 总市值：43.14亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 822,199,978.17 | 399,068,578.25 | 1,200,327,933.81 | 792,553,431.27 |
| 营业收入 | 822,199,978.17 | 399,068,578.25 | 1,200,327,933.81 | 792,553,431.27 |
| 二、营业总成本 | 709,473,026.97 | 358,778,707.57 | 1,229,801,069.41 | 838,141,263.93 |
| 营业成本 | 595,628,602.21 | 301,383,750.13 | 1,004,267,693.89 | 662,167,979.36 |
| 税金及附加 | 5,115,071.64 | 2,579,728.94 | 10,508,494.04 | 7,340,513.41 |
| 销售费用 | 36,647,084.76 | 17,052,315.63 | 59,253,062.89 | 44,509,417.85 |
| 管理费用 | 30,228,169.93 | 14,904,871.45 | 59,484,458.7 | 52,357,035.94 |
| 研发费用 | 31,532,356.02 | 14,377,751.93 | 55,797,216.51 | 38,952,745.03 |
| 财务费用 | 10,321,742.41 | 8,480,289.49 | 40,490,143.38 | 32,813,572.34 |
| 其中:利息费用 | 11,619,512.87 | 9,162,902.53 | 42,664,265.18 | 34,195,217.14 |
| 其中:利息收入 | 985,958.83 | 660,018.52 | 1,839,973.64 | 1,458,036.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,488,537.35 | 8,711,382.63 | -23,638,504.81 | -37,453,462.24 |
| 加:投资收益 | 3,616,674.49 | 654,816.22 | 8,185,502.6 | 7,430,344.39 |
| 资产减值损失(新) | -1,715,569.31 | -751,649.79 | -1,340,697.97 | -1,582,610.81 |
| 信用减值损失(新) | -426,709.92 | -3,220,185.13 | 680,278.53 | 3,939,216.38 |
| 其他收益 | 14,072,359.71 | 5,184,773.97 | 16,501,434.1 | 12,119,476.6 |
| 四、营业利润 | 135,762,243.52 | 50,869,008.58 | -29,085,123.15 | -61,134,868.34 |
| 加:营业外收入 | 162,025.38 | 94,067.7 | 390,029.8 | 77,279.57 |
| 减:营业外支出 | 2,349,705.68 | 281,877.52 | 278,326.13 | 146,031.82 |
| 五、利润总额 | 133,574,563.22 | 50,681,198.76 | -28,973,419.48 | -61,203,620.59 |
| 减:所得税费用 | 16,028,730.27 | 5,903,701.64 | -9,200,254.6 | -13,587,630.42 |
| 六、净利润 | 117,545,832.95 | 44,777,497.12 | -19,773,164.88 | -47,615,990.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 117,545,832.95 | 44,777,497.12 | -19,773,164.88 | -47,615,990.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 117,181,542.91 | 44,496,959.41 | -20,155,591.43 | -47,658,306.03 |
| 少数股东损益 | 364,290.04 | 280,537.71 | 382,426.55 | 42,315.86 |
| 扣除非经常损益后的净利润 | 99,300,985.54 | 34,090,746.15 | -16,238,593.64 | -32,397,301.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.66 | 0.27 | -0.12 | -0.29 |
| (二)稀释每股收益 | 0.66 | 0.25 | -0.12 | -0.29 |
| 八、其他综合收益 | -1,167,402.03 | - | - | -767,307.88 |
| 归属于母公司股东的其他综合收益 | -1,167,402.03 | - | - | -767,307.88 |
| 九、综合收益总额 | 116,378,430.92 | 44,777,497.12 | -19,773,164.88 | -48,383,298.05 |
| 归属于母公司股东的综合收益总额 | 116,014,140.88 | 44,496,959.41 | -20,155,591.43 | -48,425,613.91 |
| 归属于少数股东的综合收益总额 | 364,290.04 | 280,537.71 | 382,426.55 | 42,315.86 |
| 公告日期 | 2025-08-06 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |